Overview
Cat #: AK-230_KIT
Size: 8 Vials
Form: Lyophilized
Alomone Labs is pleased to offer the Glycine Receptor Antibody Explorer Kit (#AK-230). This Explorer Kit includes antibodies targeting glycine receptors along with their respective peptide control antigen. An ideal tool for screening purposes.
For research purposes only, not for human use
Compounds
| Product Name | Cat # | Size |
|---|---|---|
Anti-Glycine Receptor α1 Antibody |
AGR-001 | 1 x 50 µl |
Glycine Receptor α1 Blocking Peptide |
BLP-GR001 | 1 x 40 µg |
Anti-Glycine Receptor α3 Antibody |
AGR-003 | 1 x 50 µl |
Glycine Receptor α3 Blocking Peptide |
BLP-GR003 | 1 x 40 µg |
Anti-Glycine Receptor α4 (extracellular) Antibody |
AGR-015 | 1 x 50 µl |
Glycine Receptor α4 (extracellular) Blocking Peptide |
BLP-GR015 | 1 x 40 µg |
Anti-Glycine Receptor β Antibody |
AGR-014 | 1 x 50 µl |
Glycine Receptor β Blocking Peptide |
BLP-GR014 | 1 x 40 µg |
Scientific Background
Scientific Background The amino acid glycine, mediates neuronal inhibition by activating glycine receptors (GlyRs), which are ligand-gated chloride channels of the nicotinic acetylcholine receptor superfamily. GlyRs are known to mediate postsynaptic inhibition in spinal cord, brain stem and some higher brain regions1. GlyR is a member of the pentameric Cys-loop ion channel receptor family. Functional Cys-loop receptors comprise homomeric or heteromeric pentameric oligomers with each of the five subunits arranged symmetrically in a ring around a central ion-conducting pore. Several developmentally and regionally regulated GlyR isoforms exist, which result from a differential expression of the GlyR α (α1- α4) and β subunit genes. Each GlyR subunit comprises a large extracellular amino-terminal domain that harbors the ligand-binding sites and the eponymous Cys-loop. This connects to a bundle of four α-helical transmembrane domains (labelled M1–M4) with a large intracellular domain between M3 and M4 and a short extracellular C-terminal tail2.
References
- Meyer, G. et al. (1995) Neuron 15, 563.
- Lynch, J.W. et al. (2009) Neuropharmacology 56, 303.
